SCHEMBL2907160

SCHEMBL2907160

c1ccc(CN2CCc3nc(C4CC4)ccc3C2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
RAB9A P51151 3/20 0.57
MEN1 O00255 2/20 0.57
NPC1 O15118 2/20 0.57
DHFR P00374 1/20 0.51
MAPT P10636 5/20 0.47
TP53 P04637 3/20 0.47
IKZF2 Q9UKS7 1/20 0.46
PNMT P11086 1/20 0.45
CFTR P13569 1/20 0.45
C5AR1 P21730 1/20 0.44
ACHE P22303 1/20 0.44
ALDH1A1 P00352 3/20 0.43
GAA P10253 3/20 0.43
KDM4E B2RXH2 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GLA P06280 1/20 0.43
HPGD P15428 1/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5776313 0.93 MEN1 (0.53) KMT2ARAB9AMEN1NPC1DHFR
Hydrochloric Acid SCHEMBL5775003 0.91 RAB9A (0.51) KMT2ARAB9AMEN1NPC1DHFR
SCHEMBL16210349 0.90 KMT2A (0.51) KMT2ARAB9AMEN1NPC1DHFR
SCHEMBL5774440 0.89 RAB9A (0.49) KMT2ARAB9AMEN1NPC1DHFR
SCHEMBL13100451 0.82 MEN1 (0.61) KMT2ARAB9AMEN1NPC1DHFR
SCHEMBL17984056 0.81 KMT2A (0.60) KMT2ARAB9AMEN1NPC1DHFR
SCHEMBL29883119 0.81 KMT2A (0.63) KMT2ARAB9AMEN1NPC1DHFR
SCHEMBL1038680 0.81 KMT2A (0.63) KMT2ARAB9AMEN1NPC1DHFR
SCHEMBL16220609 0.80 MEN1 (0.61) KMT2ARAB9AMEN1NPC1DHFR
SCHEMBL12706737 0.80 MEN1 (0.61) KMT2ARAB9AMEN1NPC1DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107207532-B Nitroimidazole derivatives against tuberculosis 南京明德新药研发股份有限公司 2019-07-30 CN disclosed
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative MEDSHINE DISCOVERY INC. (CN) 2019-03-12 US disclosed
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative MEDSHINE DISCOVERY INC. (CN) 2019-03-12 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
EP-3252059-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE Medshine Discovery Inc. (CN) 2017-12-06 EP disclosed
EP-3252059-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE Medshine Discovery Inc. (CN) 2017-12-06 EP disclosed
CN-107207532-A Nitroimidazole derivatives against tuberculosis 南京明德新药研发股份有限公司 2017-09-26 CN disclosed
CN-106946909-A The nitro imidazole derivatives for the treatment of pulmonery tuberculosis disease 南京明德新药研发股份有限公司 2017-07-14 CN disclosed
WO-2016119706-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE 南京明德新药研发股份有限公司 2016-08-04 WO disclosed
EP-2789338-A2 Condensed pyridine derivate and use thereof Takeda Pharmaceutical Company Limited (JP) 2014-10-15 EP disclosed
US-20100266504-A1 CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-21 US disclosed
EP-2216023-A1 CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE NDUFV1, NDUFV2, MT-ND4 KMT2A 3039/4885RAB9A 2868/4885MEN1 4332/4885
US-20100266504-A1 CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF HTR2C, HTR5A, HTR3C KMT2A 3157/4885RAB9A 2766/4885MEN1 4418/4885
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative NDUFV1, NDUFV2, MT-ND4 KMT2A 3039/4885RAB9A 2868/4885MEN1 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.